Pfizer Oncology Sponsored Abstracts
2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Last Updated: May 19, 2023
The majority of Annual Meeting abstracts will be released at 5:00 PM ET on Thursday, May 25, 2023. Late-Breaking Abstracts (LBAs) will be released at 7:00 AM (CT) on the day of scientific presentation at the meeting.

Key:
Oral presentation
Poster discussion

Biosimilars			
Pfizer Asset	**Abstract Number/Study/Abstract Title**	**Type**	**Date/Time**
Biosimilars	**6613** An assessment of the provider financial risk impacts of adoption of biosimilars in the Medicare Oncology Care Model.	Poster Presentation	June 3 1:15-4:15 PM CDT
Breast Cancer			
Pfizer Asset	**Abstract Number/Study/Abstract Title**	**Type**	**Date/Time**
ARV-471	**TPS1121** – **TACTIVE-U** TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.	Poster Presentation	June 4 8:00-11:00 AM CDT
ARV-471	**TPS1122** – **VERITAC-2** VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.	Poster Presentation	June 4 8:00-11:00 AM CDT
EOD	**3009** – **C4391001** First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.	Poster Discussion	June 3 Session: 1:15-2:45 PM CDT Discussion: 1:15 PM CDT
EOD	**3010** – **C4161001** First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.	Poster Discussion	June 3 Session: 1:15-2:45 PM CDT Discussion: 1:15 PM CDT

EOD	**1054** – **C4551001** First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors.	Poster Presentation	June 4 8:00-11:00 AM CDT
Palbociclib	**1018** – **PALOMAGE** First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.	Poster Discussion	June 4 Session: 11:30 AM-1:00 PM CDT Discussion: 11:42 AM CDT
Palbociclib	**TPS10069** – **A5481092** Evaluation of palbociclib in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory neuroblastoma.	Poster Presentation	June 5 1:15-4:15 PM CDT
Genitourinary Cancers (Bladder, Prostate and Renal Cell Carcinoma)			
Pfizer Asset	**Abstract Number/Study/Abstract Title**	**Type**	**Date/Time**
Axitinib	**e16553** Updated analysis of real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States.	Publication Only	N/A
Avelumab	**4515** – **JAVELIN Bladder 100** Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis.	Poster Discussion	June 3 Session: 3:00-4:30 PM CDT Discussion: 3:34 PM CDT
Avelumab	**4516** – **JAVELIN Bladder 100** Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.	Poster Discussion	June 3 Session: 3:00-4:30 PM CDT Discussion: 3:34 PM CDT
Avelumab	**4567** Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC).	Poster Presentation	June 3 8:00-11:00 AM CDT
Avelumab	**e16559** The evolution of treatment patterns in patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) and clinical outcomes: Results of a longitudinal observational cohort study in England.	Publication Only	N/A

Enzalutamide	**5026** Longitudinal transcriptome profiling of localized hormone-sensitive tumors in treatment-naïve ENACT patients with prostate cancer with and without enzalutamide (ENZA).	Poster Presentation	June 3 8:00-11:00 AM CDT
Enzalutamide	**e17081** Real-world baseline characteristics and first-line (1L) treatment (Tx) in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC) by disease volume.	Publication Only	N/A
Enzalutamide	**e17085** Outcomes of patients (pts) with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who progressed to metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TRUMPET registry.	Publication Only	N/A
Relugolix	**5078** Assessing racial differences in time to treatment escalation following androgen-deprivation therapy among veterans with prostate cancer.	Poster Presentation	June 3 8:00-11:00 AM CDT
Talazoparib	**5004** – **TALAPRO-2** TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.	Oral Presentation	June 4 Session: 8:00-11:00 AM CDT Presentation: 9:12 AM CDT
Talazoparib	**5013** – **TALAPRO-2** Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2).	Poster Discussion	June 3 Session: 1:15-2:45 PM CDT Discussion: 1:27 PM CDT
Talazoparib	**5053** – **TALAPRO-2** Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.	Poster Presentation	June 3 8:00-11:00 AM CDT
Talazoparib	**5056** – **TALAPRO-2** Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).	Poster Presentation	June 3 8:00-11:00 AM CDT

Hematology			
Pfizer Asset	**Abstract Number/Study/Abstract Title**	**Type**	**Date/Time**
Elranatamab	**8008** – **MagnetisMM-3; MagnetisMM-9; MagnetisMM-1** Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.	Oral Presentation	June 3 Session: 1:15-4:15 PM CDT Presentation: 3:39 PM CDT
Elranatamab	**6618** – **MagnetisMM-3** An indirect comparison of elranatamab's (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM).	Poster Presentation	June 3 1:15-4:15 PM CDT
Elranatamab	**8039** – **MagnetisMM-3** Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.	Poster Presentation	June 5 8:00-11:00 AM CDT
Elranatamab	**8040** – **MagnetisMM-3** Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.	Poster Presentation	June 5 8:00-11:00 AM CDT
Elranatamab	**8044** – **MagnetisMM-3** Identification of cytokines associated with response and cytokine release syndrome: Analysis of MagnetisMM-3 cohort A.	Poster Presentation	June 5 8:00-11:00 AM CDT
Elranatamab	**8045** – **MagnetisMM-3** Genomic analysis to identify determinants of inherent response and resistance to elranatamab in MagnetisMM-3 cohort A.	Poster Presentation	June 5 8:00-11:00 AM CDT
Elranatamab	**TPS8065** – **MagnetisMM-6** MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).	Poster Presentation	June 5 8:00-11:00 AM CDT
Elranatamab	**TPS8066** – **MagnetisMM-7** MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma.	Poster Presentation	June 5 8:00-11:00 AM CDT
Elranatamab	**e20021** – **MagnetisMM-1** Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1.	Publication Only	N/A

Elranatamab	**e18826** – **MagnetisMM-11** Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study.	Publication Only	N/A
Elranatamab	**e18827** – **MagnetisMM-12** Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A real-world observational chart review study.	Publication Only	N/A
Elranatamab	**e20017** – **MagnetisMM-3** Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3.	Publication Only	N/A
Elranatamab	**e20038** – **MagnetisMM-3** A matching-adjusted indirect treatment comparison of elranatamab in patients with triple-class exposed relapsed/refractory multiple myeloma: Comparisons with belantamab mafodotin, selinexor plus dexamethasone, and real-world physician's choice of treatment.	Publication Only	N/A
Precision Medicine (Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer)			
Pfizer Asset	**Abstract Number/Study/Abstract Title**	**Type**	**Date/Time**
Encorafenib + binimetinib	**9018** – **PHAROS** Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with *BRAF* V600E-mutant (*BRAF* ^{V600E}) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.	Poster Discussion	June 4 Session: 4:30-6:00 PM CDT Discussion: 4:42 PM CDT
Encorafenib + binimetinib	**TPS3627** – **BREAKWATER** BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for *BRAF* V600E-mutant metastatic colorectal cancer (mCRC).	Poster Presentation	June 5 8:00-11:00 AM CDT
Encorafenib + binimetinib	**9531** – **STARBOARD** Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).	Poster Presentation	June 3 1:15-4:15 PM CDT
Encorafenib + binimetinib	**e21506** – **HEOR** Patient characteristics and treatment patterns in BRAF-mutated unresectable or metastatic melanoma in the United States: A snapshot from real-world data.	Publication Only	N/A

EOD	**3020** – **C4481001** A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.	Poster Discussion	June 3 Session: 1:15-2:45 PM CDT Discussion: 2:11 PM CDT
EOD	**2529** – **C4401001** Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naïve advanced solid tumors.	Poster Presentation	June 3 8:00-11:00 AM CDT
EOD	**TPS3164** – **C4761001** A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.	Poster Presentation	June 3 8:00-11:00 AM CDT
Lorlatinib	**9063** – **CROWN** Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial.	Poster Presentation	June 4 8:00-11:00 AM CDT
Other/Advanced Cancers			
Pfizer Asset	**Abstract Number/Study/Abstract Title**	**Type**	**Date/Time**
Avelumab	**9537** Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.	Poster Presentation	June 3 1:15-4:15 PM CDT
Ponsegromab	**TPS12147** Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia.	Poster Presentation	June 5 1:15-4:15 PM CDT
Trillium (621/622)	**11508** – **TTI-621** Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort.	Oral Presentation	June 5 Session: 11:30 AM-2:30 PM CDT Presentation: 1:54 PM CDT